生物
毒性
嵌合抗原受体
药理学
药品
加药
限制
癌症研究
免疫疗法
免疫学
医学
内科学
免疫系统
机械工程
工程类
作者
Louai Labanieh,Robbie G. Majzner,Dorota Klysz,Elena Sotillo,Chris Fisher,José G. Vilches-Moure,Kaithlen Zen B Pacheco,Meena Malipatlolla,Peng Xu,Jessica H Hui,Surya Murty,Johanna Theruvath,Nishant A. Mehta,Sean A Yamada-Hunter,Evan W. Weber,Sabine Heitzeneder,Kevin R. Parker,Ansuman T. Satpathy,Howard Y. Chang,Michael Z. Lin,Jennifer R. Cochran,Crystal L. Mackall
出处
期刊:Cell
[Elsevier]
日期:2022-05-01
卷期号:185 (10): 1745-1763.e22
被引量:74
标识
DOI:10.1016/j.cell.2022.03.041
摘要
Regulatable CAR platforms could circumvent toxicities associated with CAR-T therapy, but existing systems have shortcomings including leakiness and attenuated activity. Here, we present SNIP CARs, a protease-based platform for regulating CAR activity using an FDA-approved small molecule. Design iterations yielded CAR-T cells that manifest full functional capacity with drug and no leaky activity in the absence of drug. In numerous models, SNIP CAR-T cells were more potent than constitutive CAR-T cells and showed diminished T cell exhaustion and greater stemness. In a ROR1-based CAR lethality model, drug cessation following toxicity onset reversed toxicity, thereby credentialing the platform as a safety switch. In the same model, reduced drug dosing opened a therapeutic window that resulted in tumor eradication in the absence of toxicity. SNIP CARs enable remote tuning of CAR activity, which provides solutions to safety and efficacy barriers that are currently limiting progress in using CAR-T cells to treat solid tumors.
科研通智能强力驱动
Strongly Powered by AbleSci AI